Amr H. Abdelhamid Ahmed

Amr H. Abdelhamid Ahmed

Auto-generated profile, based on publicly available information

Amr H. Abdelhamid Ahmed

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology‐Head and Neck Surgery, Massachusetts Eye and Ear Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in Head & Neck
Verified
Journal Article
Closed access
DSDavid C. Shonka
David C. Shonka
AHAlan Ho
Alan Ho
ACAshish V. Chintakuntlawar
Ashish V. Chintakuntlawar
JGJessica L. Geiger
Jessica L. Geiger
JPJong Chul Park
Jong Chul Park
GRGregory W. Randolph
Gregory W. Randolph

27 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HVHai Vu-Ngoc
Hai Vu-Ngoc
SESameh Samir Elawady
Sameh Samir Elawady
GMGhaleb Muhammad Mehyar
Ghaleb Muhammad Mehyar
AAAmr Hesham Abdelhamid
Amr Hesham Abdelhamid
OMOmar Mohamed Mattar
Omar Mohamed Mattar
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Systematic reviews and/or meta-analyses generally provide the best evidence for medical research. Authors are recommended to use flow diagrams to present the review process, allowing for better understanding among readers. However, no studies as of yet have assessed the quality of flow diagrams in systematic review/meta-analyses. Our study aims to evaluate the quality of systematic review/meta-analyses over a period of ten years, by assessing the quality of the flow diagrams, and the correlation to the methodological quality. Two hundred articles of “systematic review” and/or “meta-analysis” from January 2004 to August 2015 were randomly retrieved in Pubmed to be assessed for the flow diagram and methodological qualities. The flow diagrams were evaluated using a 16-grade scale corresponding to the four stages of PRISMA flow diagram. It composes four parts: Identification, Screening, Eligibility and Inclusion. Of the 200 articles screened, 154 articles were included and were assessed with AMSTAR checklist. Among them, 78 articles (50.6%) had the flow diagram. Over ten years, the proportion of papers with flow diagram available had been increasing significantly with regression coefficient beta = 5.649 (p = 0.002). However, the improvement in quality of the flow diagram increased slightly but not significantly (regression coefficient beta = 0.177, p = 0.133). Our analysis showed high variation in the proportion of articles that reported flow diagram components. The lowest proportions were 1% for reporting methods of duplicates removal in screening phase, followed by 6% for manual search in identification phase, 22% for number of studies for each specific/subgroup analysis, 27% for number of articles retrieved from each database, and 31% for number of studies included in qualitative analysis. The flow diagram quality was correlated with the methodological quality with the Pearson’s coefficient r = 0.32 (p = 0.0039). Therefore, this review suggests that the reporting quality of flow diagram is less satisfactory, hence not maximizing the potential benefit of the flow diagrams. A guideline with standardized flow diagram is recommended to improve the quality of systematic reviews, and to enable better reader comprehension of the review process.

25 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HVHuy Gia Vuong
Huy Gia Vuong
AAAhmed M.A. Altibi
Ahmed M.A. Altibi
AAAmr Hesham Abdelhamid
Amr Hesham Abdelhamid
PNPhuong Uyen Duong Ngoc
Phuong Uyen Duong Ngoc
VQVo Duy Quan
Vo Duy Quan
TKTetsuo Kondo
Tetsuo Kondo
Background: The genetic alterations of papillary thyroid carcinoma (PTC) have been reported to change over the past few decades. We performed this systematic review to further examine the trends and modifications of patient demographic, clinicopathological features and molecular profiles of PTC over time.

10 November 2021 in Thyroid®
Verified
Journal Article
Closed access
WLWhitney Liddy
Whitney Liddy
CWChe-Wei Wu
Che-Wei Wu
GDGianlorenzo Dionigi
Gianlorenzo Dionigi
GDGianluca Donatini
Gianluca Donatini
YSYasemin Giles Senyurek
Yasemin Giles Senyurek
GRGregory W. Randolph
Gregory W. Randolph
Background: The recurrent laryngeal nerve (RLN) can be injured during thyroid surgery, which can negatively affect a patient's quality of life. The impact of intraoperative anatomic variations of the RLN on nerve injury remains unclear. Objectives of this study were to (1) better understand the detailed surgical anatomic variability of the RLN with a worldwide perspective; (2) establish potential correlates between intraoperative RLN anatomy and electrophysiologic responses; and (3) use the information to minimize complications and assure accurate and safe intraoperative neuromonitoring (IONM). Methods: A large international registry database study with prospectively collected data was conducted through the International Neural Monitoring Study Group (INMSG) evaluating 1000 RLNs at risk during thyroid surgery using a specially designed online data repository. Monitored thyroid surgeries following standardized IONM guidelines were included. Cases with bulky lymphadenopathy, IONM failure, and failed RLN visualization were excluded. Systematic evaluation of the surgical anatomy of the RLN was performed using the International RLN Anatomic Classification System. In cases of loss of signal (LOS), the mechanism of neural injury was identified, and functional evaluation of the vocal cord was performed. Results: A total of 1000 nerves at risk (NARs) were evaluated from 574 patients undergoing thyroid surgery at 17 centers from 12 countries and 5 continents. A higher than expected percentage of nerves followed an abnormal intraoperative trajectory (23%). LOS was identified in 3.5% of NARs, with 34% of LOS nerves following an abnormal intraoperative trajectory. LOS was more likely in cases of abnormal nerve trajectory, fixed splayed or entrapped nerves (including at the ligament of Berry), extensive neural dissection, cases of cancer invasion, or when lateral lymph node dissection was needed. Traction injury was found to be the most common form of RLN injury and to be less recoverable than previous reports. Conclusions: Multicenter international studies enrolling diverse patient populations can help reshape our understanding of surgical anatomy during thyroid surgery. There can be significant variability in the anatomic and intraoperative characteristics of the RLN, which can impact the risk of neural injury.

31 May 2022 in The Laryngoscope
Verified
Journal Article
Closed access
BWBo WANG
Bo WANG
JZJing Zheng
Jing Zheng
JYJia‐Fan Yu
Jia‐Fan Yu
SLSi‐Ying Lin
Si‐Ying Lin
SYShou‐Yi Yan
Shou‐Yi Yan
WZWenxin Zhao
Wenxin Zhao

12 February 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KIKenji Iida
Kenji Iida
AAAmr H. Abdelhamid Ahmed
Amr H. Abdelhamid Ahmed
ANAkiko Kawano Nagatsuma
Akiko Kawano Nagatsuma
TSTomoko Shibutani
Tomoko Shibutani
SYSatoru Yasuda
Satoru Yasuda
TAToshinori Agatsuma
Toshinori Agatsuma
Currently, the only approved treatments for gastrointestinal stromal tumor (GIST) are tyrosine kinase inhibitors (TKI), which eventually lead to the development of secondary resistance mutations in KIT or PDGFRA and disease progression. Herein, we identified G protein–coupled receptor 20 (GPR20) as a novel non–tyrosine kinase target in GIST, developed new GPR20 IHC, and assessed GPR20 expression in cell lines, patient-derived xenografts, and clinical samples from two institutes (United States and Japan). We studied GPR20 expression stratified by treatment line, KIT expression, GIST molecular subtype, and primary tumor location. We produced DS-6157a, an anti-GPR20 antibody–drug conjugate with a novel tetrapeptide-based linker and DNA topoisomerase I inhibitor exatecan derivative (DXd). DS-6157a exhibited GPR20 expression–dependent antitumor activity in GIST xenograft models including a GIST model resistant to imatinib, sunitinib, and regorafenib. Preclinical pharmacokinetics and safety profile of DS-6157a support its clinical development as a potential novel GIST therapy in patients who are refractory or have resistance or intolerance to approved TKIs. Significance: GPR20 is selectively expressed in GIST across all treatment lines, regardless of KIT/PDGFRA genotypes. We generated DS-6157a, a DXd-based antibody–drug conjugate that exhibited antitumor activity in GIST models by a different mode of action than currently approved TKIs, showing favorable pharmacokinetics and safety profiles. This article is highlighted in the In This Issue feature, p. 1307